Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood

BACKGROUND: While programmed cell death receptor 1 (PD-1) blockade treatment has revolutionized treatment of patients with melanoma, clinical outcomes are highly variable, and only a fraction of patients show durable responses. Therefore, there is a clear need for predictive biomarkers to select pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Rad Pour, Soudabeh, Pico de Coaña, Yago, Demorentin, Xavier Martinez, Melief, Jeroen, Thimma, Manjula, Wolodarski, Maria, Gomez-Cabrero, David, Hansson, Johan, Kiessling, Rolf, Tegner, Jesper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108662/
https://www.ncbi.nlm.nih.gov/pubmed/33963011
http://dx.doi.org/10.1136/jitc-2020-002171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108662/
https://www.ncbi.nlm.nih.gov/pubmed/33963011
http://dx.doi.org/10.1136/jitc-2020-002171

Ejemplares similares